Industry News

21 October 2026

Dr. Reddy’s Receives DCGI Approval for Zytorvi

Dr. Reddys Laboratories Ltd announced that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

16 October 2026

Mankind Pharma to Invest 48 Million euro in Belgian Biotech Firm for 70% Stake, Enters Next-Generation CAR-T Therapy Market

Mankind Pharma Limited has entered into a definitive agreement to acquire a 70% stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for cancer.

16 October 2026

Lilly’s Omvoh Shows Promising One-Year Disease Control Results in Ulcerative Colitis and Crohn’s Disease

Eli Lilly and Company has announced new analyses of clinical trial data showing that its drug Omvoh (mirikizumab-mrkz) helped some patients with moderately to severely active ulcerative colitis and Crohn’s disease achieve multiple treatment goals simultaneously at one year.

15 October 2026

Biocon Resolves Global Patent Dispute With Genentech, Secures Pebrilzo Launch for Major Markets

Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a member of the Roche Group, resolving pending disputes over Pebrilzo® (bPertuzumab), its biosimilar version of Perjeta® (pertuzumab), a biologic medicine used in the treatment of HER2-positive breast cancer.

13 October 2026

Zydus and Formycon Achieve Keytruda Biosimilar Milestone as USFDA Accepts FYB206 Application for Review

Zydus Lifesciences Limited and Formycon AG have announced that the US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda® (pembrolizumab), for review.

9 October 2026

Viatris to Acquire Pacira BioSciences in 1.65 USD Billion Deal

Viatris Inc. has agreed to acquire Pacira BioSciences Inc. in an all-cash transaction valued at approximately 1.65 billion USD, marking a significant step in its strategy to expand its innovative medicines business.

9 October 2026

Pfizer TUKYSA Gets FDA Approval for HER2+ Breast Cancer Maintenance

Pfizer has announced that the US Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

9 October 2026

BMS Reports 42-Month Progression-Free Survival with ZENBEXUS Combination in Multiple Myeloma Trial

Bristol Myers Squibb (BMS) has announced positive results from its Phase III EXCALIBER-RRMM study, demonstrating superior progression-free survival with ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.

9 October 2026

Roche Wins FDA Approval for Tecentriq-Based Immunotherapy Regimen in Stage III Colon Cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of stage III deficient mismatch repair (dMMR) colon cancer.

8 October 2026

Halozyme Expands Subcutaneous Drug Delivery Footprint as It Enforces Keytruda Patent and Broadens argenx Partnership

Halozyme Therapeutics is strengthening its position in subcutaneous drug delivery through two developments announced within a day of each other : a Dutch court ruling that restricts Merck’s Keytruda SC activities across multiple European markets.

Dr. Reddy’s Receives DCGI Approval for Zytorvi

RECOMMENDED POSTS

Subscribe with us

Jobs by Category